LENZ Therapeutics, Inc.LENZEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
LENZ Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing novel ophthalmic therapies. Its lead product candidates address presbyopia, the age-related loss of near vision, catering to global patient groups with unmet medical needs in the eye care sector.
LENZ Q3 FY2025 Key Financial Metrics
Revenue
$12.5M
Gross Profit
N/A
Operating Profit
$-18.9M
Net Profit
$-16.7M
Gross Margin
N/A
Operating Margin
-151.1%
Net Margin
-133.6%
YoY Growth
N/A
EPS
$-0.59
LENZ Therapeutics, Inc. Q3 FY2025 Financial Summary
LENZ Therapeutics, Inc. reported revenue of $12.5M for Q3 FY2025, with a net profit of $-16.7M (down 63.5% YoY) (-133.6% margin).
Key Financial Metrics
| Total Revenue | $12.5M |
|---|---|
| Net Profit | $-16.7M |
| Gross Margin | N/A |
| Operating Margin | -151.1% |
| Report Period | Q3 FY2025 |
LENZ Therapeutics, Inc. Quarterly Revenue & Net Profit History
LENZ Therapeutics, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $12.5M | — | $-16.7M | -133.6% |
| Q2 FY2025 | $5.0M | — | $-14.9M | -298.2% |
| Q3 FY2024 | $0 | — | $-10.2M | N/A |
| Q2 FY2024 | $0 | — | $-10.3M | N/A |
Income Statement
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $5.0M | $12.5M |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | $202.6M | $224.0M | $217.3M | $210.7M |
| Liabilities | $9.7M | $8.7M | $11.0M | $16.8M |
| Equity | $192.9M | $215.3M | $206.4M | $193.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Operating CF | $-15.8M | $-10.6M | $-11.5M | $-8.6M |